文献速递类风湿关节炎

托珠单抗治疗类风湿关节炎较利妥昔单抗或阿巴西普增加憩室炎及消化道穿孔风险

Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

基于法国三个观察性注册研究,采用倾向性评分加权比较托珠单抗(TCZ)与利妥昔单抗(RTX)或阿巴西普(ABA)治疗RA患者憩室炎和消化道穿孔(GIP)风险。结果显示TCZ组憩室炎风险显著升高(HR=3.1),因憩室炎导致的GIP风险也升高(HR=3.8),总体GIP风险升高(HR=2.9),且事件发生更早、临床表现不典型。

要点

  • TCZ较RTX/ABA显著增加憩室炎风险(HR=3.1,95%CI 1.5-6.3)。
  • TCZ增加因憩室炎导致的GIP风险(HR=3.8)及总体GIP风险(HR=2.9)。
  • TCZ组憩室炎/GIP发生更早,临床表现不典型(30%慢传输),急性期反应物较低。

核心结论

  • TCZ治疗RA较RTX或ABA增加憩室炎及因憩室炎导致的GIP风险。
  • TCZ组GIP风险增加可能归因于憩室炎风险增加且临床表现具有误导性。

研究设计与样本

  • 基于法国三个观察性注册研究的 population-based 研究,纳入接受TCZ、RTX或ABA治疗的RA患者。
  • 采用倾向性评分逆概率加权法比较憩室炎或GIP风险。

主要发现

  • TCZ组憩室炎风险较RTX/ABA组升高:HR=3.1(95%CI 1.5-6.3),P=0.002。
  • TCZ组因憩室炎导致的GIP风险升高:HR=3.8(95%CI 1.1-13.6),P=0.04。
  • TCZ组总体GIP风险升高:HR=2.9(95%CI 1.1-7.8),P=0.03;其他病因所致GIP风险无显著升高。
  • TCZ组憩室炎和GIP在末次输注后发生更早(P=0.01),临床表现不典型(慢传输30%,P=0.04),事件时急性期反应物较低(P=0.005)。

临床怎么用

  • 对接受TCZ治疗的RA患者应警惕憩室炎及GIP风险,尤其注意不典型临床表现和低急性期反应物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of diverticulitis and gastrointestinal perforation (GIP) in RA treated with tocilizumab (TCZ) compared with rituximab (RTX) and abatacept (ABA). METHODS: We conducted a population-based study using three observational French registries on TCZ, RTX and ABA in RA. Using a propensity score approach, we compared the risk of diverticulitis or GIP in these patients. RESULTS: With inverse probability weighting, there was an increased risk of diverticulitis in TCZ-treated patients compared with RTX- or ABA-treated patients [hazard ratio (HR)=3.1 (95% CI: 1.5, 6.3), P =0.002]. Moreover, patients treated with TCZ had also an increased risk of GIP due to diverticulitis compared with those treated with RTX or ABA [HR=3.8 (1.1-13.6), P =0.04], resulting in an overall increased risk of GIP [HR=2.9 (1.1-7.8), P =0.03], while no significant increased risk of GIP due to any other aetiology was found in TCZ treated patients. Diverticulitis and GIP occurred earlier with TCZ than other drugs after the last perfusion (P =0.01), with atypical clinical presentation (slow transit in 30%, P =0.04) and lower acute-phase reactants at the time of the event (P =0.005). CONCLUSION: TCZ for RA was associated with increased odds of diverticulitis as well as GIP due to diverticulitis as compared with RTX and ABA. Our study confirms the increased odds of GIP in patients receiving TCZ, which might be explained by an increased risk of diverticulitis with misleading clinical presentation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rempenault C, Lukas C, Combe B, et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (Oxford). 2022. PMID: 33993216. doi:10.1093/rheumatology/keab438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。